Antigen‐Specific T‐Cell Response from Dendritic Cell Vaccination Using Cancer Stem‐Like Cell‐Associated Antigens

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Stem Cells

• Publication date

  2009-08-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1002/stem.102PMID 19536809PMCID PMC5854496
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Expression of glioma-associated antigens in pediatric brain stem and non-brain stem gliomas

  2008cited by this paper
• Increased Seroreactivity to Glioma-Expressed Antigen 2 in Brain Tumor Patients under Radiation

  2008cited by this paper
• Prostate stem cell antigen vaccination induces a long-term protective immune response against prostate cancer in the absence of autoimmunity.

  2008cited by this paper
• Nitrosoureas inhibit the stathmin-mediated migration and invasion of malignant glioma cells.

  2008cited by this paper
• Hedgehog Signaling Regulates Brain Tumor‐Initiating Cell Proliferation and Portends Shorter Survival for Patients with PTEN‐Coexpressing Glioblastomas

  2008cited by this paper
• Frequent and specific immunity to the embryonal stem cell–associated antigen SOX2 in patients with monoclonal gammopathy

  2007cited by this paper
• Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of patients with malignant gliomas

  2007cited by this paper
• Expression of MHC I and NK ligands on human CD133+ glioma cells: possible targets of immunotherapy

  2007cited by this paper
• Spheres Isolated from 9L Gliosarcoma Rat Cell Line Possess Chemoresistant and Aggressive Cancer Stem‐Like Cells

  2007cited by this paper
• DC-based cancer vaccines.

  2007cited by this paper
• Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines.

  2006cited by this paper
• Recent advances in the treatment of malignant astrocytoma.

  2006cited by this paper
• Expression of MHC I and NK ligands on human CD133 + glioma cells: possible targets of immunotherapy

  2006cited by this paper
• Neurospheres enriched in cancer stem-like cells are highly effective in eliciting a dendritic cell-mediated immune response against malignant gliomas.

  2006cited by this paper
• Identification of interleukin-13 receptor alpha2 peptide analogues capable of inducing improved antiglioma CTL responses.

  2006cited by this paper
• Dendritic Cell Vaccination in Glioblastoma Patients Induces Systemic and Intracranial T-cell Responses Modulated by the Local Central Nervous System Tumor Microenvironment

  2005cited by this paper
• Low immunogenicity of in vitro-expanded human neural cells despite high MHC expression.

  2005cited by this paper
• Cytotoxic T cell targeting of TRP-2 sensitizes human malignant glioma to chemotherapy

  2005cited by this paper
• HER-2, gp100, and MAGE-1 Are Expressed in Human Glioblastoma and Recognized by Cytotoxic T Cells

  2004cited by this paper
• Identification of human brain tumour initiating cells

  2004cited by this paper
• Isolation of cancer stem cells from adult glioblastoma multiforme

  2004cited by this paper
• Recent progress in immunotherapy for malignant glioma: treatment strategies and results from clinical trials.

  2004cited by this paper
• AIM-2: A Novel Tumor Antigen is Expressed and Presented by Human Glioma Cells

  2004cited by this paper
• Molecular and Functional Analysis of Tyrosinase-Related Protein (TRP)-2 as a Cytotoxic T Lymphocyte Target in Patients With Malignant Glioma

  2003cited by this paper
• Cancer genesis: stem tumour cells as an MHC-null/HSP70 - very high 'primordial self' escaping both MHC-restricted and MHC-non- restricted immunesurveillance.

  2001cited by this paper
• Treatment of a glioblastoma patient by vaccination with autologous dendritic cells pulsed with allogeneic major histocompatibility complex class I-matched tumor peptides

  2000cited by this paper
• Treatment of a patient by vaccination with autologous dendritic cells pulsed with allogeneic major histocompatibility complex class I-matched tumor peptides. Case Report.

  2000cited by this paper

• Prophylactic and therapeutic CSC-based vaccination reduced tumor growth, metastasis and enhanced survival in mouse model of breast cancer.

  2026cites this paper
• Peptide‑based therapeutic strategies for glioma: current state and prospects.

  2025cites this paper
• Macrophage-derived dendritic cells enhance antitumor immunity in a mouse model of head and neck squamous cell carcinoma

  2025cites this paper
• Breaking Immunosuppression to Enhance Cancer Stem Cell-Targeted Immunotherapy

  2025cites this paper
• Immunotherapy for High-Grade Gliomas

  2025cites this paper
• Genomic landscapes and therapeutic perspectives of cancer stem cells in the tumor microenvironment

  2025cites this paper
• Cancer Stem Cells Connecting to Immunotherapy: Key Insights, Challenges, and Potential Treatment Opportunities

  2025cites this paper
• Immunologic specificity in glioblastoma: Antigen discovery and translational implications

  2025cites this paper
• Glioblastoma vaccines: past, present, and opportunities

  2024cites this paper
• Dissecting SOX2 expression and function reveals an association with multiple signaling pathways during embryonic development and in cancer progression.

  2024cites this paper
• Improvement of current immunotherapies with engineered oncolytic viruses that target cancer stem cells

  2024cites this paper
• Dendritic cell therapy for neurospoagioma: Immunomodulation mediated by tumor vaccine

  2024cites this paper
• Immunotherapeutic Strategies Targeting Breast Cancer Stem Cells

  2024cites this paper
• Dendritic cells pulsed with penetratin-OLFM4 inhibit the growth and metastasis of melanoma in mice.

  2024cites this paper
• Challenges and opportunities for cancer stem cell‐targeted immunotherapies include immune checkpoint inhibitor, cancer stem cell‐dendritic cell vaccine, chimeric antigen receptor immune cells, and modified exosomes

  2024cites this paper
• Cancer stem cell markers: Symphonic masters of chemoresistance and immune evasion.

  2024cites this paper
• Psc-Dependent Stem Cell Engineering for Management of Cancer and Its Current Challenges

  2024cites this paper
• Tumor microenvironment of cancer stem cells: Perspectives on cancer stem cell targeting

  2023cites this paper
• Progress of PD-1/PD-L1 signaling in immune response to liver transplantation for hepatocellular carcinoma

  2023cites this paper
• Update on immune‐based therapy strategies targeting cancer stem cells

  2023cites this paper
• Melanoma stem cell vaccine induces effective tumor immunity against melanoma

  2023cites this paper
• Oncolytic viral therapy as promising immunotherapy against glioma

  2023cites this paper
• T Cell Immune Algorithm: A Novel Nature-Inspired Algorithm for Engineering Applications

  2023cites this paper
• Tumor microenvironment-induced tumor cell plasticity: relationship with hypoxic stress and impact on tumor resistance

  2023cites this paper
• The metabolic addiction of cancer stem cells

  2022cites this paper
• Impact of Cancer Stem Cells and Cancer Stem Cell-Driven Drug Resiliency in Lung Tumor: Options in Sight

  2022cites this paper
• Efficacy of Whole Cancer Stem Cell-Based Vaccines: A Systematic Review of Preclinical and Clinical Studies.

  2022cites this paper
• Decorating Bacteria with Triple Immune Nanoactivators Generates Tumor-Resident Living Immunotherapeutics.

  2022cites this paper
• Glioma Stem Cells Upregulate CD39 Expression to Escape Immune Response through SOX2 Modulation

  2022cites this paper
• Advances in Immunotherapy for the Treatment of Adult Glioblastoma: Overcoming Chemical and Physical Barriers

  2022cites this paper
• Vaccination as a therapeutic strategy for Nasopharyngeal carcinoma.

  2022cites this paper
• Signaling pathways in the regulation of cancer stem cells and associated targeted therapy

  2022cites this paper
• Dendritic cell vaccines for glioblastoma fail to complete clinical translation: Bottlenecks and potential countermeasures.

  2022cites this paper
• The Cancer Stem Cell Marker CD44 Play Key Roles in Immune Suppression/Evasion, Drug Resistance, Epithelial-Mesenchymal Transition, and Metastasis in Several Human Cancers

  2021cites this paper
• Machine learning revealed stemness features and a novel stemness-based classification with appealing implications in discriminating the prognosis, immunotherapy and temozolomide responses of 906 glioblastoma patients

  2021cites this paper
• Cellular Immunotherapy Targeting Cancer Stem Cells: Preclinical Evidence and Clinical Perspective

  2021cites this paper
• Cancer Stem Cell Marker CD44 Plays Multiple Key Roles in Human Cancers: Immune Suppression/Evasion, Drug Resistance, Epithelial–Mesenchymal Transition, and Metastasis

  2021cites this paper
• Molecular Mechanisms of Drug Resistance in Glioblastoma

  2021cites this paper
• Melanoma Stem Cell Vaccine Modified with IL-33 Induces Anti-Tumor Immunity by Activating CD8+T Cells

  2021cites this paper
• Immunotherapy for targeting cancer stem cells in hepatocellular carcinoma

  2021cites this paper
• Dendritic cells loaded with exosomes derived from cancer stem cell‐enriched spheroids as a potential immunotherapeutic option

  2021cites this paper
• Biomaterials for Advanced Personalized Therapeutic Approaches

  2021cites this paper
• The role of peptidases and their endogenous inhibitors in the regulation of NK cell cytotoxicity

  2021cites this paper
• Overcoming biological barriers to improve solid tumor immunotherapy

  2021cites this paper
• Glioblastoma Stem Cells as a Therapeutic Target

  2020cites this paper
• CD44, a marker of cancer stem cells, is positively correlated with PD-L1 expression and immune cells infiltration in lung adenocarcinoma

  2020cites this paper
• Influence of Innate Immunity on Cancer Cell Stemness

  2020cites this paper
• Immunotherapy: Newer Therapeutic Armamentarium against Cancer Stem Cells

  2020cites this paper
• Immunotherapeutics for head and neck squamous cell carcinoma stem cells

  2020cites this paper
• Immunopathology as a Basis for Immunotherapy of Head and Neck Squamous Cell Carcinoma

  2020cites this paper
• Dendritic cells transduced with glioma-expressed antigen 2 recombinant adenovirus induces specific cytotoxic lymphocyte response and anti-tumor effect in mice

  2020cites this paper
• A new strategy for enhancing antitumor immune response using dendritic cells loaded with chemo-resistant cancer stem-like cells in experimental mice model.

  2019cites this paper
• A Randomized Double-Blind Placebo-Controlled Phase II Trial of Dendritic Cell Vaccine ICT-107 in Newly Diagnosed Patients with Glioblastoma

  2019cites this paper
• Mathematical Modelling of Cancer Stem Cell-Targeted Immunotherapy.

  2019cites this paper
• An effective dendritic cell‐based vaccine containing glioma stem‐like cell lysate and CpG adjuvant for an orthotopic mouse model of glioma

  2019cites this paper
• Dual-targeted therapeutic strategy combining CSC–DC-based vaccine and cisplatin overcomes chemo-resistance in experimental mice model

  2019cites this paper
• Cancer Stem Cells: The Players of Immune Evasion from Immunotherapy

  2019cites this paper
• A New Approach for Cancer Immunotherapy Based on the Cancer Stem Cell Antigens Properties.

  2019cites this paper
• Crosstalk Between Prostate Cancer Stem Cells and Immune Cells: Implications for Tumor Progression and Resistance to Immunotherapy

  2019cites this paper
• Current approaches and challenges in the molecular therapeutic targeting of glioblastoma.

  2019cites this paper
• Cancer Stem Cell Resistance to Targeted Therapy

  2019cites this paper
• Vitae

  2019cites this paper
• Harnessing Radiation Biology to Augment Immunotherapy for Glioblastoma

  2019cites this paper
• Targeting signalling pathways and the immune microenvironment of cancer stem cells — a clinical update

  2019cites this paper
• Cancer stem cell immunology and immunotherapy: Harnessing the immune system against cancer's source.

  2019cites this paper
• A Characterization of Dendritic Cells and Their Role in Immunotherapy in Glioblastoma: From Preclinical Studies to Clinical Trials

  2019cites this paper
• Aldehyde dehydrogenase-positive melanoma stem cells in tumorigenesis, drug resistance and anti-neoplastic immunotherapy

  2019cites this paper
• Immunogenicity of Tumor Initiating Stem Cells: Potential Applications in Novel Anticancer Therapy

  2019cites this paper
• A concise review of immunotherapy for glioblastoma

  2018cites this paper
• Brain Tumor Treatment: 2017 Update

  2018cites this paper
• Cancer stem cells as targets for DC-based immunotherapy of colorectal cancer

  2018cites this paper
• Cancer stem cells: Regulation programs, immunological properties and immunotherapy.

  2018cites this paper
• Targeted Theranostic Nanoparticles for Brain Tumor Treatment

  2018cites this paper
• [Immunotherapy Against Head and Neck Cancer Stem Cells].

  2017cites this paper
• Chapter 9: Update on Nanoparticle‒Mediated Immune Mechanisms for Dendritic Cell-Based Targeted Immunity and Cancer

  2017cites this paper
• Glia to glioma: A wrathful journey

  2017cites this paper
• Immuno-oncology of Dormant Tumours

  2017cites this paper
• Immunotherapy against metastatic bladder cancer by combined administration of granulocyte macrophage‐colony stimulating factor and interleukin‐2 surface modified MB49 bladder cancer stem cells vaccine

  2017cites this paper
• Identification of T cell target antigens in glioblastoma stem-like cells using an integrated proteomics-based approach in patient specimens

  2017cites this paper
• Advances in Immunotherapy for Glioblastoma Multiforme

  2017cites this paper
• Cancer Stem Cells in Squamous Cell Carcinoma.

  2017cites this paper
• Therapeutic vaccination based on side population cells transduced by the granulocyte–macrophage colony-stimulating factor gene elicits potent antitumor immunity

  2017cites this paper
• Dendritic‐cell‐based immunotherapy evokes potent anti‐tumor immune responses in CD105+ human renal cancer stem cells

  2017cites this paper
• Therapeutic vaccination based on side population cells transduced by the granulocyte–macrophage colony-stimulating factor gene elicits potent antitumor immunity

  2017cites this paper
• Characterization and functional analysis of a slow-cycling subpopulation in colorectal cancer enriched by cell cycle inducer combined chemotherapy

  2017cites this paper
• Hide-and-seek: the interplay between cancer stem cells and the immune system

  2017cites this paper
• Soluble HLA-associated peptide from PSF1 has a cancer vaccine potency

  2017cites this paper
• Advances in Monitoring Cell-Based Therapies with Magnetic Resonance Imaging: Future Perspectives

  2017cites this paper
• Immuntherapie gegen Tumorstammzellen bei Plattenepithel­ karzinomen im Kopf­Hals­Bereich Immunotherapy Against Head and Neck Cancer Stem Cells

  2017cites this paper
• Immuntherapie gegen Tumorstammzellen bei Plattenepithelkarzinomen im Kopf-Hals-Bereich

  2017cites this paper
• Dendritic cell based immunotherapy using tumor stem cells mediates potent antitumor immune responses.

  2016cites this paper
• Analysis of cytotoxic T lymphocytes response activated dendritic cells vaccination using breast cancer stem-like cells

  2016cites this paper
• Immune evasion in glioma

  2016cites this paper
• Exploiting the Immunogenic Potential of Cancer Cells for Improved Dendritic Cell Vaccines

  2016cites this paper
• Prioritization schema for immunotherapy clinical trials in glioblastoma

  2016cites this paper
• Immunotherapy in glioblastoma: emerging options in precision medicine.

  2016cites this paper
• Targeted Therapies for Glioma Stem Cells

  2016cites this paper
• Oral Cancer: Novel Concepts for the Oral Health Care Practitioner

  2016cites this paper
• Targeting Cancer Stem Cells in Oral Cancer.

  2016cites this paper
• Characteristics of liver cancer stem cells and clinical correlations.

  2016cites this paper